Press Releases
Apr 20, 2020
Strategic Review Update including Formal Sale Process Appointment of Noble Capital Markets, Inc.
Mar 31, 2020
Announcement of Strategic Review, Termination of R&D Programme, Update on EU GlioKIDS Grant, Directorate Changes
Jan 8, 2020
Positive Results from MTD201-102 Study Support Subcutaneous Route for Long-Acting Octreotide Product
Dec 5, 2019
Midatech Pharma announces confirmation of a €2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and fatal form of childhood brain cancer
Oct 28, 2019
Midatech Pharma PLC Announces Closing of US$3.0 Million Registered Direct Offering
Oct 24, 2019
Midatech's MTX110 Receives Orphan Designation for DIPG
Oct 8, 2019
Commencement of MTD201 Phase 1 Study
Sep 11, 2019
Receipt of Spanish Government Loan for the scale up of MTD201 commercial manufacturing facility
Sep 9, 2019
Directorate Change
Jul 19, 2019
MTX102 Safety Results
Jul 3, 2019
MTX110 Update
Jun 13, 2019
MTD201 Development Plan
May 13, 2019
Midatech will be presenting at an investor evening hosted by Turner Pope Investments, on Monday 13 May 2019
Apr 24, 2019
Financial results for year ended 31 December 2018
Feb 26, 2019
Finalisation of Strategic Investment and Licence Agreement
Feb 25, 2019
Midatech raises £13.4m in Placing, Subscription and over-subscribed Open Offer
Feb 5, 2019
Shareholder Circular, Open Offer & Notice of General Meeting Panel Waiver
Feb 4, 2019
Proposed Placing and Open Offer
Feb 4, 2019
Result of the Placing - Launch of the Open Offer
Jan 29, 2019
Midatech Secures Strategic Investment & Announces Licence Agreement with China Medical Systems
Jan 10, 2019
Midatech announces EUR 1.5 million loan facility
Dec 21, 2018
Corporate update and potential fundraise
Dec 20, 2018
Midatech Announces Q-Sphera™ Microsphere Technology Partnership
Sep 28, 2018
Interim results from MTD201 exploratory study
Sep 28, 2018
Shareholder Circular and Notice of General Meeting to be held on 15 October 2018
Jun 8, 2018
Midatech Pharma US enrols first patient in Gelclair® trial in stem cell transplant
Jun 1, 2018
Board Change
Jun 1, 2018
2017 Annual Report and AGM Notification
May 25, 2018
Midatech commences US clinical study of its investigational treatment for fatal childhood brain cancer
Mar 21, 2018
Midatech commences dosing in equivalence study
Mar 15, 2018
Midatech announces changes in Senior Management Team
Jan 9, 2018
Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved
Jan 2, 2018
Midatech enters into a Loan Agreement with MidCap Financial
Dec 20, 2017
Midatech Pharma US initiates Gelclair® Phase IV trial to study oral mucositis in stem cell transplant patients
Sep 6, 2017
Midatech to present at 19th Annual Rodman & Renshaw Global Investment Conference
Sep 4, 2017
Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly
Jul 26, 2017
Completion of pre-clinical liver cancer programme
Jul 18, 2017
Trading Update and Notice of Results
May 22, 2017
Midatech announces progress update on brain cancer therapies
Apr 11, 2017
Notice of Annual General Meeting 2017
Apr 4, 2017
Audited financial results for the year ended 31 December 2016
Mar 10, 2017
Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility
Jan 10, 2017
Trading Update and Notice of Results
Nov 22, 2016
Midatech provides update on agreement with Emergex Vaccines
Nov 15, 2016
Midatech selects MTR104 candidate for treatment of liver cancer
Sep 30, 2016
Commencement of First in Human Immunotherapy Study Using Gold Nanoparticle Technology
Sep 21, 2016
Midatech Pharma US Announces Partnership with R-Pharm US to Co-promote Zuplenz® (ondansetron) oral soluble film and Oravig® (miconazole) orally-dissolving buccal tablet
Sep 2, 2016
Interim results for the six months ended 30 June 2016